Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 1× · see citing works

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686 · see citing works

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,962 · see citing works

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853 · see citing works

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,405 · see citing works

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Zhang, L., Jackson, C. B., Mou, H., Ojha, A., Peng, H., Quinlan, B. D., Rangarajan, E. S., Pan, A., Vanderheiden, A., Suthar, M. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19808-4 · Cited by 1,387 · see citing works

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729069 · Cited by 1,239 · see citing works

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

Li, L., Zhang, W. J., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,207 · see citing works

Convalescent plasma as a potential therapy for COVID-19

Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038 · see citing works

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claër, L., Quentric, P., Fadlallah, J., Devilliers, H., Ghillani, P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd2223 · Cited by 1,037 · see citing works

Use of convalescent plasma therapy in SARS patients in Hong Kong

Cheng, Y., Wong, R. S. M., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P. K. S., Wong, K. C., Leung, C. B., & Cheng, G. Y.-M. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 953 · see citing works

The convalescent sera option for containing COVID-19

Casadevall, A., & Pirofski, L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 904 · see citing works

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

Hofmann, H., Pyrc, K., van der Hoek, L., Geier, M., Berkhout, B., & Pöhlmann, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409465102 · Cited by 824 · see citing works

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B. H., Winters, J. L., van Buskirk, C. M., Grossman, B. J., Joyner, M. J., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 798 · see citing works

Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection

Hung, I. F., To, K. K., Lee, C. K., Lee, K., Chan, K., Yan, W.-W., Liu, R. W., Watt, C., Chan, W.-M., Lai, K., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 679 · see citing works

Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

ter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S.-W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 599 · see citing works

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivityPreprint

Zhang, L., Jackson, C. B., Mou, H., et al. (2020) · bioRxiv · doi:10.1101/2020.06.12.148726 · Cited by 576 · see citing works

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572 · see citing works

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Joyner, M. J., Wright, R. S., Fairweather, D., Senefeld, J. W., Bruno, K. A., Klassen, S. A., Carter, R. E., Klompas, A. M., Wiggins, C. C., Shepherd, J. R. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140200 · Cited by 472 · see citing works

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., et al. (2020) · Science · doi:10.1126/science.abc5343 · Cited by 440 · see citing works

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infectionPreprint

Seow, J., Graham, C., Merrick, B., Acors, S., Steel, K., Hemmings, O., O'Bryne, A., Kouphou, N., Pickering, S., Rui, G.-L. P., et al. (2020) · medRxiv · doi:10.1101/2020.07.09.20148429 · Cited by 411 · see citing works

Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience

Ko, J. H., Seok, H., Cho, S. Y., Ha, Y. E., Baek, J. Y., Ys, K., Kim, Y., Park, J. K., Chung, C. R., Kang, E., et al. (2017) · Antiviral Therapy · doi:10.3851/imp3243 · Cited by 323 · see citing works

Untitled work

(2020) · doi:10.1101/2020.04.15.20066407 · Cited by 278 · see citing works

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

Adams, E. R., Ainsworth, M. A., Anand, R., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E. J., Beer, S., Bell, J. I., Berry, T., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15927.1 · Cited by 278 · see citing works

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100126 · Cited by 197 · see citing works

SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members — USS Theodore Roosevelt, April 2020

Payne, D. C., Smith-Jeffcoat, S. E., Nowak, G., Chukwuma, U., Geibe, J. R., Hawkins, R. J., Johnson, J. A., Thornburg, N. J., Schiffer, J. M., Weiner, Z. P., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6923e4 · Cited by 195 · see citing works

The membrane‐proximal intracytoplasmic tyrosine residue of HIV‐1 envelope glycoprotein is critical for basolateral targeting of viral budding in MDCK cells

Lodge, R., Lalonde, J., Lemay, G., & Cohen, É. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.4.695 · Cited by 186 · see citing works

IgA dominates the early neutralizing antibody response to SARS-CoV-2Preprint

Sterlin, D., Mathian, A., Miyara, M., et al. (2020) · medRxiv · doi:10.1101/2020.06.10.20126532 · Cited by 175 · see citing works

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

Perreault, J., Tremblay, T., Fournier, M., Drouin, M., Beaudoin-Bussières, G., Prévost, J., Lewin, A., Bégin, P., Finzi, A., & Bazin, R. (2020) · Blood · doi:10.1182/blood.2020008367 · Cited by 118 · see citing works

A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals

Casadevall, A., Joyner, M. J., & Pirofski, L. (2020) · JAMA · doi:10.1001/jama.2020.10218 · Cited by 102 · see citing works

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674 · see citing works

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., et al. (2020) · Science · doi:10.1126/science.abe8499 · Cited by 900 · see citing works

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H.-X., Lee, W. S., Wragg, K. M., Kelly, H. G., Esterbauer, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21444-5 · Cited by 351 · see citing works

SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond

Bettini, E., & Locci, M. (2021) · Vaccines · doi:10.3390/vaccines9020147 · Cited by 283 · see citing works

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Crawford, K. H. D., Dingens, A. S., Eguia, R., Wolf, C. R., Wilcox, N., Logue, J. K., Shuey, K., Casto, A. M., Fiala, B., Wrenn, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa618 · Cited by 265 · see citing works

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265 · see citing works

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Bégin, P., Callum, J., Jamula, E., Cook, R. J., Heddle, N. M., Tinmouth, A. T., Zeller, M. P., Beaudoin-Bussières, G., Amorim, L., Bazin, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01488-2 · Cited by 258 · see citing works

Humoral Responses and Serological Assays in SARS-CoV-2 Infections

Galipeau, Y., Greig, M., Liu, C., Driedger, M., & Langlois, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610688 · Cited by 239 · see citing works

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

Ullah, I., Prévost, J., Ladinsky, M., Stone, H., Lu, M.-L., Anand, S., Beaudoin-Bussières, G., Symmes, K., Benlarbi, M., Ding, S.-L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.015 · Cited by 152 · see citing works

Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles

Lu, M., Uchil, P. D., Li, W., Zheng, D., Terry, D. S., Gorman, J., Shi, W., Zhang, B., Zhou, T., Ding, S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.001 · Cited by 194 · see citing works

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Prévost, J., Gasser, R., Beaudoin-Bussières, G., Richard, J., Duerr, R., Laumaea, A., Anand, S. P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100126 · Cited by 197 · see citing works

Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases

Carsetti, R., Zaffina, S., Mortari, E. P., Terreri, S., Corrente, F., Capponi, C., Palomba, P., Mirabella, M., Cascioli, S., Palange, P., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610300 · Cited by 195 · see citing works

Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production

Chen, Y., Zuiani, A., Fischinger, S., Mullur, J., Atyeo, C. G., Travers, M. E., Lelis, F., Pullen, K. M., Martin, H., Tong, P., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.051 · Cited by 179 · see citing works

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Anand, S., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard, N., Laumaea, A., Gong, S., Bourassa, C., et al. (2021) · bioRxiv · doi:10.1016/j.xcrm.2021.100290 · Cited by 177 · see citing works

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.001 · Cited by 187 · see citing works

SARS-CoV-2 Seropositivity and Subsequent Infection Risk in Healthy Young Adults: A Prospective Cohort StudyPreprint

Letizia, A. G., Ge, Y., Vangeti, S., Goforth, C. W., Weir, D. L., Kuzmina, N. A., Balinsky, C. A., Chen, H. W., Ewing, D. F., Schanoski, A. S., et al. (2021) · SSRN Electronic Journal · doi:10.1016/s2213-2600(21)00158-2 · Cited by 148 · see citing works

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galão, R. P., Dupont, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.023 · Cited by 130 · see citing works

COVID-19: Rethinking the Lockdown Groupthink

Joffe, A. R. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.625778 · Cited by 153 · see citing works

Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern

Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S. Y., Tauzin, A., Gasser, R., Vézina, D., Anand, S. P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110210 · Cited by 125 · see citing works

The scientific and ethical feasibility of immunity passports

Brown, R. C. H., Kelly, D. F., Wilkinson, D., & Savulescu, J. (2020) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(20)30766-0 · Cited by 111 · see citing works

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset

Perreault, J., Tremblay, T., Fournier, M., Drouin, M., Beaudoin-Bussières, G., Prévost, J., Lewin, A., Bégin, P., Finzi, A., & Bazin, R. (2020) · Blood · doi:10.1182/blood.2020008367 · Cited by 118 · see citing works

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

Gasser, R., Cloutier, M., Prévost, J., Fink, C., Ducas, É., Ding, S., Dussault, N., Landry, P., Tremblay, T., Laforce‐Lavoie, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108790 · Cited by 122 · see citing works

A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection

Beaudoin-Bussières, G., Chen, Y., Ullah, I., Prévost, J., Tolbert, W. D., Symmes, K., Ding, S., Benlarbi, M., Gong, S. Y., Tauzin, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110368 · Cited by 120 · see citing works

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

Dupont, L., Snell, L., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 98 · see citing works

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.004 · Cited by 103 · see citing works

Functional importance of the D614G mutation in the SARS-CoV-2 spike protein

Jackson, C. B., Zhang, L., Farzan, M., & Choe, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.026 · Cited by 90 · see citing works

The success of SARS-CoV-2 vaccines and challenges ahead

Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 90 · see citing works

Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity

Gong, S. Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D., Goyette, G., Gendron‐Lepage, G., et al. (2021) · Virology · doi:10.1016/j.virol.2021.09.001 · Cited by 80 · see citing works

Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses

Ibarrondo, F. J., Hofmann, C., Fulcher, J. A., Goodman‐Meza, D., Mu, W., Hausner, M. A., Ali, A., Balamurugan, A., Taus, E., Elliott, J. E., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c03972 · Cited by 78 · see citing works

Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents

Koerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 72 · see citing works

Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection of a Healthcare Worker in a Belgian Nosocomial Outbreak Despite Primary Neutralizing Antibody Response

Selhorst, P., van Ierssel, S. H., Michiels, J., Mariën, J., Bartholomeeusen, K., Dirinck, E. L., Vandamme, S., Jansens, H., & Ariën, K. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1850 · Cited by 77 · see citing works

The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2

Bauer, G. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.061 · Cited by 76 · see citing works

Covid-19 vaccine immunogenicity in people living with HIV-1

Nault, L., Marchitto, L., Goyette, G., Tremblay-Sher, D., Fortin, C., Martel‐Laferrière, V., Trottier, B., Richard, J., Durand, M., Kaufmann, D., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.090 · Cited by 74 · see citing works

An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models

Schepens, B., van Schie, L., Nerinckx, W., Roose, K., Breedam, W. V., Fijałkowska, D., Devos, S., Weyts, W., Cae, S. D., Vanmarcke, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi7826 · Cited by 66 · see citing works

Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19

Harrington, W. E., Trakhimets, O., Andrade, D. V., Dambrauskas, N., Raappana, A., Jiang, Y., Houck, J., Selman, W., Yang, A., Vigdorovich, V. I., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100253 · Cited by 64 · see citing works

SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors

Terpos, E., Stellas, D., Rosati, M., Sergentanis, T. Ν., Hu, X., Politou, M., Pappa, V., Ntanasis‐Stathopoulos, I., Karaliota, S., Bear, J., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.010 · Cited by 66 · see citing works

Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2

Prévost, J., Richard, J., Gasser, R., Ding, S., Fage, C., Anand, S. P., Adam, D., Vergara, N. G., Tauzin, A., Benlarbi, M., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101151 · Cited by 61 · see citing works

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality

Brunet‐Ratnasingham, E., Anand, S. P., Gantner, P., Dyachenko, A., Moquin‐Beaudry, G., Brassard, N., Beaudoin-Bussières, G., Pagliuzza, A., Gasser, R., Benlarbi, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5629 · Cited by 53 · see citing works

The Circulating Proteome─Technological Developments, Current Challenges, and Future Trends

Geyer, P. E., Hornburg, D., Pernemalm, M., Hauck, S. M., Palaniappan, K. K., Albrecht, V., Dagley, L. F., Moritz, R. L., Yu, X., Edfors, F., et al. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00586 · Cited by 57 · see citing works

Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy

Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 57 · see citing works

Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection

Gerhards, C., Thiaucourt, M., Kittel, M., Becker, C., Ast, V., Hetjens, M., Neumaier, M., & Haselmann, V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.080 · Cited by 55 · see citing works

One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term Symptoms

Rank, A., Tzortzini, A., Kling, E., Schmid, C., Claus, R., Loell, E., Burger, R., Römmele, C., Dhillon, C., Müller, K., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153305 · Cited by 52 · see citing works

Vaccination versus infection with SARS‐CoV‐2: Establishment of a high avidity IgG response versus incomplete avidity maturation

Struck, F., Schreiner, P. A., Staschik, E., Wochinz‐Richter, K., Schulz, S., Soutschek, E., Motz, M., & Bauer, G. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27270 · Cited by 48 · see citing works

Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis

Muecksch, F., Wise, H., Templeton, K., Batchelor, B., Squires, M., McCance, K., Jarvis, L., Malloy, K., Furrie, E., Richardson, C., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00090-8 · Cited by 34 · see citing works

Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study

Schaffner, A., Risch, L., Aeschbacher, S., Risch, C., Weber, M. C., Thiel, S. L., Jüngert, K., Pichler, M., Grossmann, K., Wohlwend, N., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123989 · Cited by 48 · see citing works

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses

Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110429 · Cited by 47 · see citing works

COVID ‐19 and plasma cells: Is there long‐lived protection?*

Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 44 · see citing works

Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection

Wright, P. F., Prevost-Reilly, A., Natarajan, H., Brickley, E. B., Connor, R. I., Wieland‐Alter, W., Miele, A. S., Weiner, J. A., Nerenz, R. D., & Ackerman, M. E. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac065 · Cited by 44 · see citing works

Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis

Goupil, R., Benlarbi, M., Beaubien-Souligny, W., Nadeau-Fredette, A.-C., Chatterjee, D., Goyette, G., Gunaratnam, L., Lamarche, C., Tom, A., Finzi, A., et al. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.210673 · Cited by 39 · see citing works

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesPreprint

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435972 · Cited by 41 · see citing works

Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership

Herrington, D. M., Sanders, J. W., Wierzba, T. F., Alexander‐Miller, M. A., Espeland, M. A., Bertoni, A. G., Mathews, A., Seals, A. L., Munawar, I., Runyon, M. S., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06517-6 · Cited by 35 · see citing works

The challenge of avidity determination in SARS‐CoV‐2 serology

Bauer, G., Struck, F., Schreiner, P. A., Staschik, E., Soutschek, E., & Motz, M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26863 · Cited by 36 · see citing works

Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay

Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E. J., Manguiat, K., Lindsay, L. R., Wood, H., DREBOT, M. A., Dibernardo, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab220 · Cited by 35 · see citing works

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine

Tauzin, A., Nicolas, A., Ding, S., Benlarbi, M., Medjahed, H., Chatterjee, D., Dionne, K., Gong, S. Y., Gendron‐Lepage, G., Bo, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.111998 · Cited by 34 · see citing works

Perception of Health, Mistrust, Anxiety, and Indecision in a Group of Italians Vaccinated against COVID-19

Moccia, G., Carpinelli, L., Savarese, G., Borrelli, A., Boccia, G., Motta, O., Capunzo, M., & Caro, F. D. (2021) · Vaccines · doi:10.3390/vaccines9060612 · Cited by 34 · see citing works

Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects

Zhang, J., Xing, S., Liang, D., Hu, W. G., Ke, C., He, J., Yuan, R., Huang, Y., Li, Y., Liu, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.791660 · Cited by 34 · see citing works

Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection

Schasfoort, R. B. M., van Weperen, J., van Amsterdam, M., Parisot, J., Hendriks, J., Koerselman, M., Karperien, M., Mentink, A., Bennink, M. L., Krabbe, H. G., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113165 · Cited by 31 · see citing works

Milk From Women Diagnosed With COVID-19 Does Not Contain SARS-CoV-2 RNA but Has Persistent Levels of SARS-CoV-2-Specific IgA Antibodies

Pace, R. M., Williams, J. E., Järvinen, K. M., Meehan, C. L., Martin, M. A., Ley, S. H., Barbosa‐Leiker, C., Andres, A., Yeruva, L., Belfort, M. B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.801797 · Cited by 33 · see citing works

Multicenter Evaluation of the Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of 10 High-Throughput Serological Assays Used in Clinical Laboratories

Therrien, C., Serhir, B., Bélanger-Collard, M., Skrzypczak, J., Shank, D. K., Renaud, C., Girouard, J., Loungnarath, V., Carrier, M., Brochu, G., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02511-20 · Cited by 32 · see citing works

The intestinal microbiota and improving the efficacy of COVID-19 vaccinations

Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104850 · Cited by 32 · see citing works

Single-Molecule FRET Imaging of Virus Spike–Host Interactions

Lu, M. (2021) · Viruses · doi:10.3390/v13020332 · Cited by 35 · see citing works

Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins

Anand, S. P., Chen, Y., Prévost, J., Gasser, R., Beaudoin-Bussières, G., Abrams, C. F., Pazgier, M., & Finzi, A. (2020) · Viruses · doi:10.3390/v12101104 · Cited by 31 · see citing works

Antigenic variation of SARS‐CoV‐2 in response to immune pressure

Forni, D., Cagliani, R., Pontremoli, C., Mozzi, A., Pozzoli, U., Clerici, M., & Sironi, M. (2020) · Molecular Ecology · doi:10.1111/mec.15730 · Cited by 30 · see citing works

Identification of SARS-CoV-2–specific immune alterations in acutely ill patients

Rébillard, R., Charabati, M., Grasmuck, C., Filali-Mouhim, A., Tastet, O., Brassard, N., Daigneault, A., Bourbonnière, L., Anand, S. P., Balthazard, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145853 · Cited by 31 · see citing works

Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization

Ding, S., Laumaea, A., Benlarbi, M., Beaudoin-Bussières, G., Gasser, R., Medjahed, H., Pancera, M., Stamatatos, L., McGuire, A. T., Bazin, R., et al. (2020) · Viruses · doi:10.3390/v12111214 · Cited by 30 · see citing works

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern

Wagner, T. R., Schnepf, D., Beer, J., Klingel, K., Ruetalo, N., Kaiser, P. D., Junker, D., Sauter, M., Traenkle, B., Frecot, D. I., et al. (2021) · EMBO Reports · doi:10.15252/embr.202153865 · Cited by 27 · see citing works

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Peng, H. T., Rhind, S. G., & Beckett, A. (2021) · JMIR Public Health and Surveillance · doi:10.2196/25500 · Cited by 28 · see citing works

A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens

Upreti, S., & Samant, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03323-w · Cited by 29 · see citing works

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike

Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Lista, M. J., et al. (2021) · doi:10.1101/2021.02.03.429355 · Cited by 27 · see citing works

A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients

Luo, Y.-Q. R., Yun, C., Chakraborty, I., Wu, A., & Lynch, K. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00193-21 · Cited by 16 · see citing works

Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals

Gil-Manso, S., Blanco, I. M., López-Esteban, R., Carbonell, D., López-Fernández, L. A., West, L. J., Correa‐Rocha, R., & Pion, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793142 · Cited by 27 · see citing works

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

Tauzin, A., Gong, S. Y., Chatterjee, D., Ding, S., Painter, M. M., Goel, R. R., Beaudoin-Bussières, G., Marchitto, L., Boutin, M., Laumaea, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111554 · Cited by 27 · see citing works

Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19

Codina, H. C., Viéitez, I., Gutiérrez‐Valencia, A., Skouridou, V., Martínez, C., Patiño, L., Botero-Gallego, M., Trujillo‐Rodríguez, M., Serna‐Gallego, A., Muñoz‐Muela, E., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9112259 · Cited by 24 · see citing works

Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays

Valcourt, E. J., Manguiat, K., Robinson, A., Lin, Y.-C., Abe, K., Mubareka, S., Shigayeva, A., Zhong, Z., Girardin, R. C., Dupuis, A. P., et al. (2021) · Microbiology spectrum · doi:10.1128/spectrum.00886-21 · Cited by 25 · see citing works

Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a population-based study

Schaffner, A., Risch, L., Weber, M. C., Thiel, S. L., Jüngert, K., Pichler, M., Wohlwend, N., Lung, T., Ritzler, M., Hillmann, D., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1347 · Cited by 23 · see citing works

High‐throughput detection of antibodies targeting the SARS‐CoV ‐2 Spike in longitudinal convalescent plasma samples

Anand, S. P., Prévost, J., Richard, J., Perreault, J., Tremblay, T., Drouin, M., Fournier, M., Lewin, A., Bazin, R., & Finzi, A. (2021) · Transfusion · doi:10.1111/trf.16318 · Cited by 23 · see citing works

Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study

Karuna, S., Li, S. S., Grant, S., Walsh, S. R., Frank, I., Casapía, M., Trahey, M., Hyrien, O., Fisher, L. H., Miner, M. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003868 · Cited by 21 · see citing works

Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection

Tauzin, A., Gendron‐Lepage, G., Nayrac, M., Anand, S. P., Bourassa, C., Medjahed, H., Goyette, G., Dubé, M., Bazin, R., Kaufmann, D., et al. (2022) · Viruses · doi:10.3390/v14030532 · Cited by 22 · see citing works

Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing

Zhao, P.-S., Zou, J., Zhou, F., Zhu, Y., Song, Q., Yu, D.-D., & Li, X.-P. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108767 · Cited by 16 · see citing works

Epidemiological assessment of SARS-CoV-2 reinfection

Almadhi, M. A., Alsayyad, A., Conroy, R. M., Atkin, S. L., AlAwadhi, A. I., Al‐Tawfiq, J. A., & AlQahtani, M. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.07.075 · Cited by 22 · see citing works

Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies

Körper, S., Jahrsdörfer, B., Corman, V. M., Pilch, J., Wuchter, P., Blasczyk, R., Müller, R., Tonn, T., Bakchoul, T., Schäfer, R., et al. (2021) · Transfusion Medicine and Hemotherapy · doi:10.1159/000515610 · Cited by 22 · see citing works

ABO blood group is involved in the quality of the specific immune response anti-SARS-CoV-2

Gil-Manso, S., Blanco, I. M., Motyka, B., Halpin, A., López-Esteban, R., Pérez-Fernández, V. A., Carbonell, D., López-Fernández, L. A., West, L. J., Correa‐Rocha, R., et al. (2021) · Virulence · doi:10.1080/21505594.2021.2019959 · Cited by 25 · see citing works

Potential SARS-CoV-2 vaccines: Concept, progress, and challenges

Hosseini, S. A., Zahedipour, F., Mirzaei, H., & Oskuee, R. K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107622 · Cited by 21 · see citing works

Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI

Bohländer, F., Riehl, D., Weißmüller, S., Gutscher, M., Schüttrumpf, J., & Faust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.700429 · Cited by 21 · see citing works

Immune response induced by novel coronavirus infection

Sun, Y., Zou, Y., Wang, H., Cui, G., Yu, Z., & Ren, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.988604 · Cited by 20 · see citing works

An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells

Nicolas, A., Sannier, G., Dubé, M., Nayrac, M., Tauzin, A., Painter, M. M., Goel, R. R., Laporte, M., Gendron‐Lepage, G., Medjahed, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105904 · Cited by 20 · see citing works

Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern

van Rijswijck, D. M. H., Bondt, A., Hoek, M., van der Straten, K., Caniels, T. G., Poniman, M., Eggink, D., Reusken, C. B. E. M., de Bree, G. J., Sanders, R. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33899-1 · Cited by 20 · see citing works

Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection

Kučinskaitė-Kodzė, I., Simanavičius, M., Šimaitis, A., & Žvirblienė, A. (2021) · Viruses · doi:10.3390/v13112313 · Cited by 19 · see citing works

SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells

Ding, S., Adam, D., Beaudoin-Bussières, G., Tauzin, A., Gong, S. Y., Gasser, R., Laumaea, A., Anand, S. P., Privé, A., Bourassa, C., et al. (2021) · Viruses · doi:10.3390/v14010005 · Cited by 18 · see citing works

Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain

Sankhala, R. S., Dussupt, V., Chen, W., Bai, H., Martinez, E. J., Jensen, J. L., Rees, P. A., Hajduczki, A., Chang, W. C., Choe, M., et al. (2023) · Structure · doi:10.1016/j.str.2023.11.015 · Cited by 17 · see citing works

Temporal Associations of B and T Cell Immunity with Robust Vaccine Responsiveness in a 16-Week Interval BNT162B2 Regimen

Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard, N., Lima-Barbosa, R., Beaudoin-Bussières, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111013 · Cited by 18 · see citing works

VE607 stabilizes SARS-CoV-2 Spike in the “RBD-up” conformation and inhibits viral entry

Ding, S., Ullah, I., Gong, S. Y., Grover, J. R., Mohammadi, M., Chen, Y., Vézina, D., Beaudoin-Bussières, G., Verma, V. T., Goyette, G., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104528 · Cited by 17 · see citing works

Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2

Gong, S. Y., Ding, S., Benlarbi, M., Chen, Y., Vézina, D., Marchitto, L., Beaudoin-Bussières, G., Goyette, G., Bourassa, C., Bo, Y., et al. (2022) · Viruses · doi:10.3390/v14102178 · Cited by 16 · see citing works

Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques

Sankhala, R. S., Lal, K. G., Jensen, J. L., Dussupt, V., Mendez-Rivera, L., Bai, H., Wieczorek, L., Mayer, S. V., Zemil, M., Wagner, D. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44265-0 · Cited by 15 · see citing works

Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients

Dwyer, C. J., Cloud, C. A., Wang, C., Heidt, P., Chakraborty, P., Duke, T., McGue, S. R., Jeffcoat, B., Dunne, J., Johnson, L., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102489 · Cited by 15 · see citing works

Deciphering Fc-effector functions against SARS-CoV-2

Beaudoin-Bussières, G., & Finzi, A. (2024) · Trends in Microbiology · doi:10.1016/j.tim.2024.01.005 · Cited by 15 · see citing works

A trend of dropping anti‐SARS‐CoV‐2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors

Drews, S. J., Devine, D. V., McManus, J., Mendoza, E. J., Manguiat, K., Wood, H., Girardin, R. C., Dupuis, A. P., McDonough, K. A., & DREBOT, M. A. (2021) · Transfusion · doi:10.1111/trf.16364 · Cited by 15 · see citing works

Correction: Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Peng, H. T., Rhind, S. G., & Beckett, A. (2021) · JMIR Public Health and Surveillance · doi:10.2196/31554 · Cited by 16 · see citing works

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Anand, S., Prévost, J., Nayrac, M., Beaudoin-Bussières, G., Benlarbi, M., Gasser, R., Brassard, N., Laumaea, A., Gong, S., Bourassa, C., et al. (2021) · bioRxiv · doi:10.1016/j.xcrm.2021.100290 · Cited by 177 · see citing works

High‐throughput detection of antibodies targeting the SARS‐CoV ‐2 Spike in longitudinal convalescent plasma samples

Anand, S. P., Prévost, J., Richard, J., Perreault, J., Tremblay, T., Drouin, M., Fournier, M., Lewin, A., Bazin, R., & Finzi, A. (2021) · Transfusion · doi:10.1111/trf.16318 · Cited by 23 · see citing works

Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

Li, C., Yu, D., Wu, X. J., Hong, L., Zhou, Z., Xie, Y., Li, T., Wu, J., Lu, F., Feng, L. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24230-5 · Cited by 73 · see citing works

Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma

Thomopoulos, T. P., Rosati, M., Terpos, E., Stellas, D., Hu, X., Karaliota, S., Bouchla, A., Katagas, I., Antoniadou, A., Mentis, A. F., et al. (2021) · Viruses · doi:10.3390/v13091844 · Cited by 6 · see citing works

SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors

Terpos, E., Stellas, D., Rosati, M., Sergentanis, T. Ν., Hu, X., Politou, M., Pappa, V., Ntanasis‐Stathopoulos, I., Karaliota, S., Bear, J., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.010 · Cited by 66 · see citing works